1.00Open1.30Pre Close1 Volume57 Open Interest3.00Strike Price100.00Turnover166.78%IV6.10%PremiumOct 18, 2024Expiry Date0.77Intrinsic Value100Multiplier20DDays to Expiry0.23Extrinsic Value100Contract SizeAmericanOptions Type0.7843Delta0.1987Gamma3.77Leverage Ratio-0.0111Theta0.0011Rho2.96Eff Leverage0.0026Vega
Fulcrum Therapeutics Stock Discussion
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
No comment yet